EUVIMEDEUVIMED entdecken
Crossref

Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection

Weeraya Phaisal, Orwa Albitar, Pajaree Chariyavilaskul iD, Watsamon Jantarabenjakul iD, Noppadol Wacharachaisurapol, Siti Maisharah Sheikh Ghadzi, Hadzliana Zainal, Sabariah Noor Harun

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Weeraya Phaisal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Medical Diagnostic Laboratories, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Rifampin, Isoniazid, Antitubercular Agents, Arylamine N-Acetyltransferase. Die Arbeit nennt 56 Literaturangaben. Gefördert von: Thailand Science Research and Innovation Fund Chulalongkorn University, Ratchadapisek Somphot Fund, Faculty of Medicine, Chulalongkorn University, Health Systems Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Twelve weekly doses of rifapentine and isoniazid (3HP regimen) are recommended for TB preventive therapy in children with TB infection. However, they present with variability in the pharmacokinetic profiles. The current study aimed to develop a pharmacokinetic model of rifapentine and isoniazid in 12 children with TB infection using NONMEM.

Methods

Ninety plasma and 41 urine samples were collected at Week 4 of treatment. Drug concentrations were measured using a validated HPLC–UV method. MassARRAY® SNP genotyping was used to investigate genetic factors, including P-glycoprotein (ABCB1), solute carrier organic anion transporter B1 (SLCO1B1), arylacetamide deacetylase (AADAC) and N-acetyl transferase (NAT2). Clinically relevant covariates were also analysed.

Results

A two-compartment model for isoniazid and a one-compartment model for rifapentine with transit compartment absorption and first-order elimination were the best models for describing plasma and urine data. The estimated (relative standard error, RSE) of isoniazid non-renal clearance was 3.52 L·h−1 (23.1%), 2.91 L·h−1 (19.6%), and 2.58 L·h−1 (20.0%) in NAT2 rapid, intermediate and slow acetylators. A significant proportion of the unchanged isoniazid was cleared renally (2.7 L·h−1; 8.0%), while the unchanged rifapentine was cleared primarily through non-renal routes (0.681 L·h−1; 3.6%). Participants with the ABCB1 mutant allele had lower bioavailability of rifapentine, while food prolonged the mean transit time of isoniazid.

Conclusions

ABCB1 mutant allele carriers may require higher rifapentine doses; however, this must be confirmed in larger trials. Food did not affect overall exposure to isoniazid and only delayed absorption time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinIsoniazidAntitubercular AgentsArylamine N-AcetyltransferaseTuberculosisHumansMaleFemaleChildChild, PreschoolLiver-Specific Organic Anion Transporter 1GenotypePolymorphism, Single NucleotideATP Binding Cassette Transporter, Subfamily BAdolescentInfant

Substanzen

RifampinIsoniazidrifapentineAntitubercular AgentsArylamine N-AcetyltransferaseNAT2 protein, humanLiver-Specific Organic Anion Transporter 1SLCO1B1 protein, humanATP Binding Cassette Transporter, Subfamily BABCB1 protein, human

Autor:innen und Institutionen

  • Center for Medical Diagnostic Laboratories, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 USM, Penang, Malaysia.
  • Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Center of Excellence for Paediatric Infectious Diseases and Vaccines, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Thai Red Cross Emerging Infectious Diseases Clinical Centre, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

ORCID-Profile: Pajaree Chariyavilaskul, Watsamon Jantarabenjakul

Förderung

  • Thailand Science Research and Innovation Fund Chulalongkorn University
  • Ratchadapisek Somphot Fund, Faculty of Medicine, Chulalongkorn University
  • Health Systems Research Institute

Zitieren

APA

Phaisal, W., Albitar, O., Chariyavilaskul, P., Jantarabenjakul, W., Wacharachaisurapol, N., Ghadzi, S. M. S., Zainal, H., & Harun, S. N. (2024). Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae059

Vancouver

Phaisal W, Albitar O, Chariyavilaskul P, Jantarabenjakul W, Wacharachaisurapol N, Ghadzi SMS, et al. Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae059

BibTeX
@article{Phaisal2024,
  author = {Phaisal, Weeraya and Albitar, Orwa and Chariyavilaskul, Pajaree and Jantarabenjakul, Watsamon and Wacharachaisurapol, Noppadol and Ghadzi, Siti Maisharah Sheikh and Zainal, Hadzliana and Harun, Sabariah Noor},
  title = {Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae059}
}
Kostenlos starten →